ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
125.667,83
0,85%
S&P 500
6.032,38
0,56%
US Dollar vs BRL
5,97435
0,00%
Bitcoin
96.318,24
-0,12%
Brent Oil
71,98
0,00%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Menlo Therapeutics Inc (MNLO)

  7. Menlo Therapeutics Inc (MNLO) Notícias

MNLO

Menlo Therapeutics (MNLO)

Menlo Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:MNLO
DataHoraFonteTítuloCódigoCompanhia
02/06/202317:35Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:MNLOMenlo Therapeutics Inc
11/05/202317:25Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:MNLOMenlo Therapeutics Inc
11/05/202317:22Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:MNLOMenlo Therapeutics Inc
14/03/202318:14Edgar (US Regulatory)Annual Report (10-k)NASDAQ:MNLOMenlo Therapeutics Inc
25/11/202216:01Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:MNLOMenlo Therapeutics Inc
18/11/202219:01Edgar (US Regulatory)Small Company Offering and Sale of Securities Without Registration (d)NASDAQ:MNLOMenlo Therapeutics Inc
14/11/202218:51Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:MNLOMenlo Therapeutics Inc
28/07/202217:31Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:MNLOMenlo Therapeutics Inc
12/05/202218:01Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:MNLOMenlo Therapeutics Inc
15/02/202208:40Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:MNLOMenlo Therapeutics Inc
14/01/202219:22Edgar (US Regulatory)Amended Current Report Filing (8-k/a)NASDAQ:MNLOMenlo Therapeutics Inc
21/06/202118:19Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:MNLOMenlo Therapeutics Inc
17/05/202107:30Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:MNLOMenlo Therapeutics Inc
06/05/202118:03Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:MNLOMenlo Therapeutics Inc
20/04/202117:49Edgar (US Regulatory)Amended Annual Report (10-k/a)NASDAQ:MNLOMenlo Therapeutics Inc
04/03/202118:32Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:MNLOMenlo Therapeutics Inc
02/02/202117:17Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:MNLOMenlo Therapeutics Inc
05/06/202017:35Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(2) (424b2)NASDAQ:MNLOMenlo Therapeutics Inc
22/05/202009:30Business WireRobbins Geller Rudman & Dowd LLP Announce Proposed Settlement in the Menlo Therapeutics Inc. Securities SettlementNASDAQ:MNLOMenlo Therapeutics Inc
16/04/202013:47Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:MNLOMenlo Therapeutics Inc
03/03/202018:05GlobeNewswire Inc.Menlo Therapeutics Reports Fourth Quarter and Full Year 2019 Financial ResultsNASDAQ:MNLOMenlo Therapeutics Inc
26/02/202009:30GlobeNewswire Inc.Menlo Therapeutics Announces Results from Phase 2 Trial of Serlopitant in Patients with Chronic Pruritus of Unknown OriginNASDAQ:MNLOMenlo Therapeutics Inc
25/02/202021:01GlobeNewswire Inc.Menlo Therapeutics to Host Conference Call Tomorrow to Discuss Results from Phase 2 Trial of Serlopitant in Patients with Chr...NASDAQ:MNLOMenlo Therapeutics Inc
05/02/202010:30GlobeNewswire Inc.Menlo Therapeutics Announces Publication of Phase 2 Results for Serlopitant for the Treatment of Pruritus Associated with Pso...NASDAQ:MNLOMenlo Therapeutics Inc
07/01/202018:49Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:MNLOMenlo Therapeutics Inc
06/01/202018:48Edgar (US Regulatory)Registration Statement for Securities to Be Issued in Business Combination Transactions (s-4/a)NASDAQ:MNLOMenlo Therapeutics Inc
16/12/201919:15Edgar (US Regulatory)Amended Statement of Changes in Beneficial Ownership (4/a)NASDAQ:MNLOMenlo Therapeutics Inc
04/12/201919:20Edgar (US Regulatory)Securities Registration: Business Combination (s-4)NASDAQ:MNLOMenlo Therapeutics Inc
27/11/201910:00GlobeNewswire Inc.Menlo Therapeutics CEO to Participate in Fireside Chat at the Piper Jaffray 31st Annual Healthcare ConferenceNASDAQ:MNLOMenlo Therapeutics Inc
12/11/201919:09PR Newswire (US)SHAREHOLDER ALERT: WeissLaw LLP Investigates Foamix Pharmaceuticals Ltd.NASDAQ:MNLOMenlo Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:MNLO

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
PRIO3
PETRORIO ON
BOV
BHIA3
Grupo Casas Bahia ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados

BLACK FRIDAY

ADVFN

Celebrating 25 years Est 1999-2024

Economize até 50%* para TRADER BRASIL

1 ano 30%, 2 anos 40% e *3 anos 50%

*Ao longo de 3 anos $ 881.64 apenas $ 440.82